
## Marla Gearing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3334029/publications.pdf Version: 2024-02-01



MADIA GEADING

#	Article	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
3	TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nature Neuroscience, 2018, 21, 228-239.	7.1	404
4	A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. Cell Systems, 2017, 4, 60-72.e4.	2.9	381
5	Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. Nature Communications, 2014, 5, 4159.	5.8	215
6	Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nature Neuroscience, 2022, 25, 213-225.	7.1	202
7	Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Science Advances, 2020, 6, .	4.7	186
8	Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease. Scientific Data, 2018, 5, 180036.	2.4	179
9	Elevated Serum Pesticide Levels and Risk for Alzheimer Disease. JAMA Neurology, 2014, 71, 284.	4.5	173
10	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
11	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
12	Dendritic spines provide cognitive resilience against <scp>A</scp> lzheimer's disease. Annals of Neurology, 2017, 82, 602-614.	2.8	150
13	A proteomic network approach across the <scp>ALS</scp> ― <scp>FTD</scp> disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Molecular Medicine, 2018, 10, 48-62.	3.3	142
14	Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 19.	2.4	126
15	A?-peptide length aid apolipoprotein E genotype in Alzheimer's disease. Annals of Neurology, 1996, 39, 395-399.	2.8	123
16	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
17	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
18	Potassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 797-808.	1.2	87

MARLA GEARING

#	Article	IF	CITATIONS
19	Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology, 2016, 87, 1024-1030.	1.5	74
20	Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease. Scientific Data, 2020, 7, 315.	2.4	74
21	Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration. Journal of Neuroscience, 2016, 36, 1316-1323.	1.7	71
22	Quantitative phosphoproteomics of Alzheimer's disease reveals crossâ€ŧalk between kinases and small heat shock proteins. Proteomics, 2015, 15, 508-519.	1.3	70
23	Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. Proteomics, 2016, 16, 3042-3053.	1.3	69
24	RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease. Journal of Biological Chemistry, 2018, 293, 11047-11066.	1.6	66
25	Dendritic spine remodeling accompanies Alzheimer's disease pathology and genetic susceptibility in cognitively normal aging. Neurobiology of Aging, 2019, 73, 92-103.	1.5	62
26	Regional Variation in the Distribution of Apolipoprotein E and Aβ in Alzheimer's Disease. Journal of Neuropathology and Experimental Neurology, 1995, 54, 833-841.	0.9	56
27	Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2018, 11, 454.	1.4	55
28	5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer's disease modulate Tau-induced neurotoxicity. Human Molecular Genetics, 2016, 25, ddw109.	1.4	53
29	Rho Kinase II Phosphorylation of the Lipoprotein Receptor LR11/SORLA Alters Amyloid-β Production. Journal of Biological Chemistry, 2011, 286, 6117-6127.	1.6	50
30	Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease. Proteomics, 2018, 18, e1800108.	1.3	50
31	Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. Acta Neuropathologica Communications, 2020, 8, 163.	2.4	49
32	Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease. Journal of Biological Chemistry, 2014, 289, 35296-35313.	1.6	42
33	Head injury does not alter disease progression or neuropathologic outcomes in ALS. Neurology, 2015, 84, 1788-1795.	1.5	42
34	Aggregation of actin and cofilin in identical twins with juvenile-onset dystonia. Annals of Neurology, 2002, 52, 465-476.	2.8	40
35	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	0.9	35
36	Late-stage CTE pathology in a retired soccer player with dementia. Neurology, 2014, 83, 2307-2309.	1.5	33

MARLA GEARING

#	Article	IF	CITATIONS
37	Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype. Neuropathology and Applied Neurobiology, 2001, 27, 197-205.	1.8	32
38	The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6. Experimental Neurology, 2018, 308, 111-119.	2.0	32
39	Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. Acta Neuropathologica Communications, 2021, 9, 134.	2.4	32
40	Amyloid βâ€abrogated TrkA ubiquitination in <scp>PC</scp> 12 cells analogous to Alzheimer's disease. Journal of Neurochemistry, 2015, 133, 919-925.	2.1	31
41	Viscoelastic Properties of Human Autopsy Brain Tissues as Biomarkers for Alzheimer's Diseases. IEEE Transactions on Biomedical Engineering, 2019, 66, 1705-1713.	2.5	31
42	TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Communications, 2019, 1, fcz014.	1.5	28
43	Validation of machine learning models to detect amyloid pathologies across institutions. Acta Neuropathologica Communications, 2020, 8, 59.	2.4	20
44	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	3.9	19
45	Applicability of digital analysis and imaging technology in neuropathology assessment. Neuropathology, 2016, 36, 270-282.	0.7	17
46	Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain. Bioconjugate Chemistry, 2017, 28, 2627-2637.	1.8	15
47	Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives. Journal of Alzheimer's Disease, 2019, 70, 153-161.	1.2	15
48	Pro-Nerve Growth Factor Induces Activation of RhoA Kinase and Neuronal Cell Death. Brain Sciences, 2019, 9, 204.	1.1	14
49	TBK1 interacts with tau and enhances neurodegeneration in tauopathy. Journal of Biological Chemistry, 2021, 296, 100760.	1.6	14
50	Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2021, 14, 623659.	1.4	12
51	Analysis of 3- <i>O</i> -Sulfated Heparan Sulfate Using Isotopically Labeled Oligosaccharide Calibrants. Analytical Chemistry, 2022, 94, 2950-2957.	3.2	11
52	Histological Confirmation of Myelinated Neural Filaments Within the Tip of the Neurotrophic Electrode After a Decade of Neural Recordings. Frontiers in Human Neuroscience, 2020, 14, 111.	1.0	9
53	An early proinflammatory transcriptional response to tau pathology is ageâ€specific and foreshadows reduced tau burden. Brain Pathology, 2022, 32, e13018.	2.1	7
54	Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2019, 33, 327-330.	0.6	6

MARLA GEARING

#	Article	IF	CITATIONS
55	GPR37 modulates progenitor cell dynamics in a mouse model of ischemic stroke. Experimental Neurology, 2021, 342, 113719.	2.0	5
56	Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R. Neurobiology of Disease, 2020, 146, 105079.	2.1	4
57	Tau deposition in the spinal cord is not specific for CTE-ALS. Neurology, 2020, 95, 37-39.	1.5	1
58	Largeâ€scale deep multiâ€layer analysis of Alzheimer's disease brain reveals strong proteomic diseaseâ€related changes not observed at the RNA level. Alzheimer's and Dementia, 2021, 17, e055041.	0.4	1
59	Proteomics identifies CSF biomarker panels reflective of pathological networks in the Alzheimer's disease brain. Alzheimer's and Dementia, 2020, 16, e042227.	0.4	0
60	Increased <i>APOEâ€e4</i> expression is associated with reactive A1 astrocytes and may confer the difference in Alzheimer disease risk from different ancestral backgrounds. Alzheimer's and Dementia, 2020, 16, e045415.	0.4	0
61	Long-term exposure to ambient air pollution is associated with neuropathologic change of Alzheimer's Disease at Autopsy. ISEE Conference Abstracts, 2021, 2021, .	0.0	0